Yahoo
    Warsaw - Delayed Quote PLN

    Wasko S.A. (WAS.WA)

    6.90 -0.20 (-2.82%)
    At close: October 30 at 4:59:56 PM GMT+1
    Loading Chart for WAS.WA
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Novartis (SWX:NOVN) Reports Longer Survival In Advanced Kidney Cancer Trial

    Novartis (SWX:NOVN) Reports Longer Survival In Advanced Kidney Cancer Trial
    Simply Wall St. 7h ago
    St. Galler Kantonalbank (SWX:SGKN) Stock Looks Reasonable With Moderate Excess Returns

    St. Galler Kantonalbank (SWX:SGKN) Stock Looks Reasonable With Moderate Excess Returns
    Simply Wall St. 19h ago
    3 Oil Stocks Investors Are Screening As Brent Forecasts Move Higher

    3 Oil Stocks Investors Are Screening As Brent Forecasts Move Higher
    Simply Wall St. 1d ago
    French Bank Stocks Under Pressure After Fitch Warning

    French Bank Stocks Under Pressure After Fitch Warning
    Simply Wall St. 1d ago
    All You Need to Know About Novartis (NVS) Rating Upgrade to Buy

    All You Need to Know About Novartis (NVS) Rating Upgrade to Buy
    Zacks 2d ago
    Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Report 2026 | Capitalize on $11.91B Market as Novartis, Voyager and Affinia Accelerate Engineered Capsids

    Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Report 2026 | Capitalize on $11.91B Market as Novartis, Voyager and Affinia Accelerate Engineered Capsids
    GlobeNewswire 2d ago
    Global Gene Silencing Therapeutics Market Report 2026-2030 | Capitalize on 16.3% CAGR as Novartis, Alnylam, Ionis, Sarepta, and Arrowhead Accelerate RNA Delivery

    Global Gene Silencing Therapeutics Market Report 2026-2030 | Capitalize on 16.3% CAGR as Novartis, Alnylam, Ionis, Sarepta, and Arrowhead Accelerate RNA Delivery
    GlobeNewswire 2d ago
    AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling Stock

    AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling Stock
    Barrons.com 2d ago
    ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns

    ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns
    Zacks 2d ago
    Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year?

    Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year?
    Zacks 2d ago
    Eli Lilly’s tirzepatide outperforms big pharma companies in Q3

    Eli Lilly’s tirzepatide outperforms big pharma companies in Q3
    Pharmaceutical Technology 2d ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: